SCHEMBL469001

SCHEMBL469001

CCOc1ccccc1CN

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.60
MAPT P10636 3/20 0.60
NPSR1 Q6W5P4 1/20 0.60
ALDH1A1 P00352 4/20 0.57
ATM Q13315 2/20 0.49
POLB P06746 1/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.49
BLM P54132 1/20 0.49
KMT2A Q03164 1/20 0.49
PLEC Q15149 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MAPK1 P28482 1/20 0.47
GLA P06280 1/20 0.46
GRIN1 Q05586 1/20 0.45
GRIN2B Q13224 1/20 0.45
HTR7 P34969 1/20 0.45
HTR2A P28223 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31195759 1.00 L3MBTL1 (0.60) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL8356887 0.92 TAAR1 (0.56) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL8093666 0.91 L3MBTL1 (0.51) L3MBTL1MAPTNPSR1ALDH1A1ATM
Benzaldehyde SCHEMBL7802566 0.85 L3MBTL1 (0.50) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL2911943 0.83 MAPT (0.52) L3MBTL1MAPTNPSR1ATMHTR2C
SCHEMBL147184 0.83 TAAR1 (0.66) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL16106140 0.82 PNMT (0.44) L3MBTL1MAPTNPSR1ALDH1A1TAAR1
SCHEMBL5254664 0.82 L3MBTL1 (0.64) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL31054 0.82 L3MBTL1 (0.84) L3MBTL1MAPTNPSR1ALDH1A1ATM
SCHEMBL2903622 0.82 CYP1A2 (0.61) L3MBTL1MAPTNPSR1ALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111777553-A Preparation method of isoquinoline compounds 苏州大学 2020-10-16 CN claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-2035375-B1 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-01-19 EP claimed
EP-1337229-B1 IMMOBILISATION OF ACTIVE AGENTS ON FIBRES HENKEL AG & CO KGAA (DE) 2009-09-30 EP claimed
EP-1869038-B1 SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-07-08 EP claimed
EP-1401841-B1 SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2005-08-24 EP claimed
EP-1337229-A2 IMMOBILISATION OF ACTIVE AGENTS ON FIBRES Henkel Kommanditgesellschaft auf Aktien (DE) 2003-08-27 EP claimed
WO-2002043675-A2 IMMOBILISATION OF ACTIVE AGENTS ON FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2002-06-06 WO claimed
EP-1076649-A1 ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME TREGA BIOSCIENCES, INC. (US) 2001-02-21 EP claimed
US-6127381-A A MELANOCORTIN RECEPTOR LIGAND FOR REGULATING FOOD INTAKE AND BODY WEIGHT, REGULATING CYTOKINE ACTIVITY, ANTI-INFLAMMATORY ACTIVITY LION BIOSCIENCE AG (DE) 2000-10-03 US claimed
WO-1999055679-A1 ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME TREGA BIOSCIENCES, INC. (US) 1999-11-04 WO claimed
CN-118851922-A Synthesis method of ionizable lipoid and preparation method and application of nucleic acid delivery system of ionizable lipoid 中山大学·深圳 2024-10-29 CN disclosed
CN-113563245-B Substituted pyrrolidines and their use in medicine 广东东阳光药业股份有限公司 2024-10-15 CN disclosed
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME RAPPTA THERAPEUTICS OY (FI) 2024-05-30 US disclosed
WO-2024091450-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-05-02 WO disclosed
US-5514502-A STYRENE-MALEIC ANHYDRIDE MODIFIED WITH AMINE FUJI PHOTO FILM CO., LTD. (JP) 1996-05-07 US disclosed
EP-0696593-A2 Inhibitors of farnesyl protein transferase BRISTOL-MYERS SQUIBB COMPANY (US) 1996-02-14 EP disclosed
WO-1995032184-A1 SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE- BASED MOLECULES HAVING AT LEAST TWO STRUCTURAL DIVERSITY ELEMENTS ARQULE, INC. (US) 1995-11-30 WO disclosed
WO-1995027729-A1 OPIATE RECEPTOR LIGANDS CHIRON CORPORATION (US) 1995-10-19 WO disclosed
EP-0593936-A1 N-[2-hydroxy-3-(2H-benzotriazol-2-yl)benzyl]oxamides as light stabilisers ELF ATOCHEM NORTH AMERICA, INC. (US) 1994-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME PPM1A, PPP2CA, PPP3CA L3MBTL1 2827/4885MAPT 927/4885NPSR1 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.